Your shopping cart is currently empty

SGC0946 TFA is a selective inhibitor of DOT1L with an IC50 value of 0.3 nM. It induces G1 phase arrest in cancer cells by inhibiting DOT1L and reduces cellular self-renewal and metastatic potential while promoting cell differentiation. SGC0946 TFA is applicable in research for tumors such as leukemia and breast cancer and serves as a probe for studying the cellular mechanisms of DOT1L in both normal and diseased cells.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | SGC0946 TFA is a selective inhibitor of DOT1L with an IC50 value of 0.3 nM. It induces G1 phase arrest in cancer cells by inhibiting DOT1L and reduces cellular self-renewal and metastatic potential while promoting cell differentiation. SGC0946 TFA is applicable in research for tumors such as leukemia and breast cancer and serves as a probe for studying the cellular mechanisms of DOT1L in both normal and diseased cells. |
| Targets&IC50 | DOT1L:0.3 nM |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.